Theralink Technologies (Theralink Technologies) Interest Coverage : 0 (At Loss) (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Theralink Technologies Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Theralink Technologies's Operating Income for the three months ended in Dec. 2023 was $-1.55 Mil. Theralink Technologies's Interest Expense for the three months ended in Dec. 2023 was $-4.55 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Theralink Technologies's Interest Coverage or its related term are showing as below:

THER's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 156.65
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Theralink Technologies Interest Coverage Historical Data

The historical data trend for Theralink Technologies's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Theralink Technologies Interest Coverage Chart

Theralink Technologies Annual Data

Trend

Feb14

Feb15

Dec16

Dec17

Dec18

Dec19

Sep20

Sep21

Sep22

Sep23

Interest Coverage

Get a 7-Day Free Trial

Theralink Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Theralink Technologies's Interest Coverage

For the Biotechnology subindustry, Theralink Technologies's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralink Technologies's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theralink Technologies's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Theralink Technologies's Interest Coverage falls into.

Theralink Technologies Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Theralink Technologies's Interest Coverage for the fiscal year that ended in Sep. 2023 is calculated as

Here, for the fiscal year that ended in Sep. 2023, Theralink Technologies's Interest Expense was $-16.91 Mil. Its Operating Income was $-8.74 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.13 Mil.

Theralink Technologies did not have earnings to cover the interest expense.

Theralink Technologies's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Theralink Technologies's Interest Expense was $-4.55 Mil. Its Operating Income was $-1.55 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.12 Mil.

Theralink Technologies did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Theralink Technologies (OTCPK:THER) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Theralink Technologies Interest Coverage Related Terms

Thank you for viewing the detailed overview of Theralink Technologies's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralink Technologies (Theralink Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theralink Technologies Inc (OTCPK:THER) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401

Website

https://www.theralink.com

Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.

Executives

Danica Holley	director	7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Matthew Wilson Schwartz	director	15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401
Chilcott, Iii Thomas E.	officer: Chief Financial Officer	373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Jeffrey Busch	director	7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Yvonne Fors	director	1201 MONSTER RD SW STE 350, RENTON WA 98057
Michael I Ruxin	director, officer: Chief Executive Officer	HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184
Avant Diagnostics, Inc	10 percent owner	1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007
Brian Gill Barnett	officer: Chief Executive Officer	230 N SPRINGER, LOS ALTOS CA 94024
Robert Neal Holcomb	director	PO BOX 535, ROLLING FORK MS 39159
Volnie Carlos Fernando Alaman	10 percent owner, officer: Chief Operating Officer-Vitel	MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Odabachian Manuel Cosme	director, 10 percent owner, officer: Global Operations GM-Vitel	MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Daniel S. Hoverman	director	C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809
Rice Charles L Jr	director	C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk	director, officer: CFO & President	549 MILGATE PLACE, BATON ROUGE LA 70810
Jonathan Frederick Head	director, officer: Chief Executive Officer	6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817